LIGHT, a New Member of the TNF Superfamily, and Lymphotoxin α Are Ligands for Herpesvirus Entry Mediator-Reference-Cited by-同舟云学术

LIGHT, a New Member of the TNF Superfamily, and Lymphotoxin α Are Ligands for Herpesvirus Entry Mediator

Published:1998-01 Issue:1 Volume:8 Page:21-30
ISSN:1074-7613
Container-title:Immunity
language:en
Short-container-title:Immunity

Author:

Mauri Davide N,Ebner Reinhard,Montgomery Rebecca I,Kochel Kristine D,Cheung Timothy C,Yu Guo-Liang,Ruben Steve,Murphy Marianne,Eisenberg Roselyn J,Cohen Gary H,Spear Patricia G,Ware Carl F

Publisher

Elsevier BV

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference65 articles.

1. Abnormal development of secondary lymphoid tissues in lymphotoxin-β-deficient mice;Alimzhanov;Proc. Natl. Acad. Sci. USA,1997

2. Lymphotoxin is expressed as a heteromeric complex with a distinct 33-kDa glycoprotein on the surface of an activated human T cell hybridoma;Androlewicz;J. Biol. Chem,1992

3. Lymphotoxin-alpha-deficient mice;Banks;J. Immunol,1995

4. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex;Banner;Cell,1993

5. Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis;Bertin;Proc. Natl. Acad. Sci. USA,1997

Cited by 687 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LTBR acts as a novel immune checkpoint of tumor‐associated macrophages for cancer immunotherapy;iMeta;2024-09-04

2. A bioactive soluble recombinant mouse LIGHT promotes effective tumor immune cell infiltration delaying tumor growth;2024-07-30

3. Multilayered Computational Framework for Designing Peptide Inhibitors of HVEM-LIGHT Interaction;The Journal of Physical Chemistry B;2024-07-03

4. An engineered TNFR1-selective human lymphotoxin-alpha mutant delivered by an oncolytic adenovirus for tumor immunotherapy;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-06

5. Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies;Journal of Experimental & Clinical Cancer Research;2024-05-31